Experimental polymer storage disease in rabbits

Miyasaki, Kichihei

doi:10.1007/bf00471182

Cited by 12 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This pH dependence of main chain stability is valuable in several biomedical applications, where polymer-based products should be stable and functional in biological milieu (pH=7-^-7.5) but undergo depolymerization after internalization by cells. Degradation of the cell-internalized polymer is important to avoid adverse effects associated with long-term polymer deposition in cells, in the first place in the glomerular mesangium and reticuloendothelial system (26,27).…”

Section: Propertiesmentioning

confidence: 99%

Acyclic Polyacetals from Polysaccharides: Biomimetic Biomedical "Stealth" Polymers

Papisov

2001

ACS Symposium Series

View full text Add to dashboard Cite

Section: Propertiesmentioning

confidence: 99%

Acyclic Polyacetals from Polysaccharides: Biomimetic Biomedical "Stealth" Polymers

Papisov

2001

ACS Symposium Series

View full text Add to dashboard Cite

“…Synthetic poly- (amino acid) or PAA-based stealth liposomes are attractive because of their complete biodegradable nature, which reduces the risk of polymer accumulation in various organs, as has been described to occur in the case of the non-degradable polymers [ 25 , 125 , 126 ]. PAAs, such as polyglutamic acid (PGA), poly(hydroxyethyl- l -asparagine) (PHEA) and poly(hydroxyethyl- l -glutamine) (PHEG), have been used in drug delivery applications [ 127 , 128 , 129 , 130 , 131 , 132 ].…”

Section: Peg Substitutes In Lipopolymers For Surface Engineering Omentioning

confidence: 99%

Surface Engineering of Liposomes for Stealth Behavior

2013

View full text Add to dashboard Cite

Liposomes are used as a delivery vehicle for drug molecules and imaging agents. The major impetus in their biomedical applications comes from the ability to prolong their circulation half-life after administration. Conventional liposomes are easily recognized by the mononuclear phagocyte system and are rapidly cleared from the blood stream. Modification of the liposomal surface with hydrophilic polymers delays the elimination process by endowing them with stealth properties. In recent times, the development of various materials for surface engineering of liposomes and other nanomaterials has made remarkable progress. Poly(ethylene glycol)-linked phospholipids (PEG-PLs) are the best representatives of such materials. Although PEG-PLs have served the formulation scientists amazingly well, closer scrutiny has uncovered a few shortcomings, especially pertaining to immunogenicity and pharmaceutical characteristics (drug loading, targeting, etc.) of PEG. On the other hand, researchers have also begun questioning the biological behavior of the phospholipid portion in PEG-PLs. Consequently, stealth lipopolymers consisting of non-phospholipids and PEG-alternatives are being developed. These novel lipopolymers offer the potential advantages of structural versatility, reduced complement activation, greater stability, flexible handling and storage procedures and low cost. In this article, we review the materials available as alternatives to PEG and PEG-lipopolymers for effective surface modification of liposomes.

show abstract

“…The need to ensure renal elimination limits the size of non-biodegradable conjugates to below renal threshold; 25 otherwise, non-biodegradable polymers carry a risk of toxic accumulation 235 and lysosomal storage or other metabolic aberrations. 242 A further example of flexibility in conceptual design is the loading of multiple drug copies onto dendrimers, as illustrated by Fréchet and Tomalia; 243 such a design applied to infection would potentially increase the delivery of the effective payload to infection by EPR. PC, phosphatidylcholine; PEO, poly(ethylene oxide); PPO, poly(propylene oxide); PAMAM, poly(amidoamine); G4, fourth generation; DSPE, distearoyl-sn-glycero-3-phosphoethanolamine.…”

Section: Clinical Development Of Nanomedicines For Infectionmentioning

confidence: 99%

The enhanced permeability retention effect: a new paradigm for drug targeting in infection

Azzopardi

Ferguson

Thomas

2012

Journal of Antimicrobial Chemotherapy

245

167

View full text Add to dashboard Cite

Multidrug-resistant, Gram-negative infection is a major global determinant of morbidity, mortality and cost of care. The advent of nanomedicine has enabled tailored engineering of macromolecular constructs, permitting increasingly selective targeting, alteration of volume of distribution and activity/toxicity. Macromolecules tend to passively and preferentially accumulate at sites of enhanced vascular permeability and are then retained. This enhanced permeability and retention (EPR) effect, whilst recognized as a major breakthrough in anti-tumoral targeting, has not yet been fully exploited in infection. Shared pathophysiological pathways in both cancer and infection are evident and a number of novel nanomedicines have shown promise in selective, passive, size-mediated targeting to infection. This review describes the similarities and parallels in pathophysiological pathways at molecular, cellular and circulatory levels between inflammation/infection and cancer therapy, where use of this principle has been established.

show abstract

Experimental polymer storage disease in rabbits

Cited by 12 publications

References 26 publications

Acyclic Polyacetals from Polysaccharides: Biomimetic Biomedical "Stealth" Polymers

Acyclic Polyacetals from Polysaccharides: Biomimetic Biomedical "Stealth" Polymers

Surface Engineering of Liposomes for Stealth Behavior

The enhanced permeability retention effect: a new paradigm for drug targeting in infection

Contact Info

Product

Resources

About